Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
07 2021
Historique:
received: 22 10 2020
accepted: 05 02 2021
revised: 04 02 2021
pubmed: 19 3 2021
medline: 13 8 2021
entrez: 18 3 2021
Statut: ppublish

Résumé

Pathogenic variants in SCN2A cause a wide range of neurodevelopmental phenotypes. Reports of genotype-phenotype correlations are often anecdotal, and the available phenotypic data have not been systematically analyzed. We extracted phenotypic information from primary descriptions of SCN2A-related disorders in the literature between 2001 and 2019, which we coded in Human Phenotype Ontology (HPO) terms. With higher-level phenotype terms inferred by the HPO structure, we assessed the frequencies of clinical features and investigated the association of these features with variant classes and locations within the Na We identified 413 unrelated individuals and derived a total of 10,860 HPO terms with 562 unique terms. Protein-truncating variants were associated with autism and behavioral abnormalities. Missense variants were associated with neonatal onset, epileptic spasms, and seizures, regardless of type. Phenotypic similarity was identified in 8/62 recurrent SCN2A variants. Three independent principal components accounted for 33% of the phenotypic variance, allowing for separation of gain-of-function versus loss-of-function variants with good performance. Our work shows that translating clinical features into a computable format using a standardized language allows for quantitative phenotype analysis, mapping the phenotypic landscape of SCN2A-related disorders in unprecedented detail and revealing genotype-phenotype correlations along a multidimensional spectrum.

Identifiants

pubmed: 33731876
doi: 10.1038/s41436-021-01120-1
pii: S1098-3600(21)05028-0
pmc: PMC8257493
doi:

Substances chimiques

NAV1.2 Voltage-Gated Sodium Channel 0
SCN2A protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1263-1272

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : K02 NS112600
Pays : United States
Organisme : NINDS NIH HHS
ID : T32 NS091008
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS108874
Pays : United States
Organisme : Wellcome Trust
ID : 203914/Z/16/Z
Pays : United Kingdom

Références

Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58, 512–521 (2017).
doi: 10.1111/epi.13709
Heyne, H. O. et al. De novo variants in neurodevelopmental disorders with epilepsy. Nat. Genet. 50, 1048–1053 (2018).
doi: 10.1038/s41588-018-0143-7
Lindy, A. S. et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. Epilepsia. 59, 1062–1071 (2018).
doi: 10.1111/epi.14074
Truty, R. et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open. 4, 397–408 (2019).
doi: 10.1002/epi4.12348
Howell, K. B. et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 59, 1177–1187 (2018).
doi: 10.1111/epi.14087
Sanders, S. J., Campbell, A. J. & Cottrell, J. R. et al. Progress in understanding and treating SCN2A-mediated disorders. Trends Neurosci. 41, 442–456 (2018).
Boiko, T., Van Wart, A., Caldwell, J. H., Levinson, S. R., Trimmer, J. S. & Matthews, G. Functional specialization of the axon initial segment by isoform-specific sodium channel targeting. J. Neurosci. 23, 2306–2313 (2003).
doi: 10.1523/JNEUROSCI.23-06-02306.2003
Wolff, M. et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 140, 1316–1336 (2017).
doi: 10.1093/brain/awx054
Lauxmann, S. et al. Relationship of electrophysiological dysfunction and clinical severity in SCN2A-related epilepsies. Hum. Mutat. 39, 1942–1956 (2018).
doi: 10.1002/humu.23619
Sugawara, T. et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc. Natl. Acad. Sci. U. S. A. 98, 6384–6389 (2001).
doi: 10.1073/pnas.111065098
Heron, S. E. et al. Sodium-channel defects in benign familial neonatal–infantile seizures. Lancet. 360, 851–852 (2002).
doi: 10.1016/S0140-6736(02)09968-3
Sanders, S. J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 485, 237–241 (2012).
doi: 10.1038/nature10945
Ogiwara, I. et al. De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology. 73, 1046–1053 (2009).
doi: 10.1212/WNL.0b013e3181b9cebc
Nakamura, K. et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology. 81, 992–998 (2013).
doi: 10.1212/WNL.0b013e3182a43e57
Howell, K. B. et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology. 85, 958–966 (2015).
doi: 10.1212/WNL.0000000000001926
Wolff, M., Brunklaus, A. & Zuberi, S. M. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 60, S59–S67 (2019).
doi: 10.1111/epi.14935
Ben-Shalom, R., Keeshen, C. M., Berrios, K. N., An, J. Y., Sanders, S. J. & Bender, K. J. Opposing effects on NaV1.2 function underlie differences between SCN2A variants observed in individuals with autism spectrum disorder or infantile seizures. Biol. Psychiatry 82, 224–232 (2017).
doi: 10.1016/j.biopsych.2017.01.009
Fisher, R. S. et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 58, 522–530 (2017).
doi: 10.1111/epi.13670
Köhler, S. et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Res. 47, D1018–d1027 (2019).
doi: 10.1093/nar/gky1105
Helbig, I. et al. A recurrent missense variant in AP2M1 impairs clathrin-mediated endocytosis and causes developmental and epileptic encephalopathy. Am. J. Hum. Genet. 104, 1060–1072 (2019).
doi: 10.1016/j.ajhg.2019.04.001
Galer, P., Ganesan, S. & Lewis-Smith, D. et al. Semantic similarity analysis reveals robust gene-disease relationships in developmental and epileptic encephalopathies. Am. J. Hum. Genet. 107, 683–697 (2020).
Ganesan, S., Galer, P. D. & Helbig, K. L. et al. A longitudinal footprint of genetic epilepsies using automated electronic medical record interpretation. Genet. Med. 22, 2060–2070 (2020).
Son, J. H. et al. Deep phenotyping on electronic health records facilitates genetic diagnosis by clinical exomes. Am. J. Hum. Genet. 103, 58–73 (2018).
doi: 10.1016/j.ajhg.2018.05.010
Shen, F., Wang, L. & Liu, H. Phenotypic analysis of clinical narratives using Human Phenotype Ontology. Stud. Health Technol. Inform. 245, 581–585 (2017).
pubmed: 29295162 pmcid: 7466871
Stenson, P. D., Mort, M. & Ball, E. V. et al. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum. Genet. 139, 1197–1207 (2020).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
doi: 10.1038/gim.2015.30
Turro, E. et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 583, 96–102 (2020).
doi: 10.1038/s41586-020-2434-2
Resnik, P. Using information content to evaluate semantic similarity in a taxonomy. Paper presented at: 14th international joint conference on Artificial intelligence. 448–453 (IJCAI, San Francisco, CA, USA, 1995).
Landgraf, A. J. & Lee, Y. Dimensionality Reduction for Binary Data through the Projection of Natural Parameters. arXiv (2015). Available at: https://arxiv.org/abs/1510.06112 .
R Core Team. R: a language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria, 2017).
UniProt Consortium T. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 46, 2699 (2018).
doi: 10.1093/nar/gky092
Begemann, A., Acuña, M. & Zweier, M. et al. Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes. Mol. Med. 27, 6 (2019).
Brunklaus, A., Ellis, R., Reavey, E., Semsarian, C. & Zuberi, S. M. Genotype phenotype associations across the voltage-gated sodium channel family. J. Med. Genet. 51, 650–658 (2014).
doi: 10.1136/jmedgenet-2014-102608
Shi, X. Y. et al. Clinical spectrum of SCN2A mutations. Brain Dev. 34, 541–545 (2012).
doi: 10.1016/j.braindev.2011.09.016
Leach, E. L., van Karnebeek, C. D. M., Townsend, K. N., Tarailo-Graovac, M., Hukin, J. & Gibson, W. T. Episodic ataxia associated with a de novo SCN2A mutation. Eur. J. Paediatr. Neurol. 20, 772–776 (2016).
doi: 10.1016/j.ejpn.2016.05.020
Liao, Y. et al. SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology. 75, 1454–1458 (2010).
doi: 10.1212/WNL.0b013e3181f8812e
Schwarz, N. et al. Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia. J. Neurol. 263, 334–343 (2016).
doi: 10.1007/s00415-015-7984-0
Suddaby, J. S., Silver, J. & So, J. Understanding the schizophrenia phenotype in the first patient with the full SCN2A phenotypic spectrum. Psychiatr. Genet. 29, 91–94 (2019).
Pesquita, C., Faria, D., Falcao, A. O., Lord, P. & Couto, F. M. Semantic similarity in biomedical ontologies. PLoS Comput. Biol. 5, e1000443 (2009).
doi: 10.1371/journal.pcbi.1000443
Shen, F. et al. HPO2Vec+: Leveraging heterogeneous knowledge resources to enrich node embeddings for the Human Phenotype Ontology. J. Biomed. Inform. 96, 103246 (2019).
doi: 10.1016/j.jbi.2019.103246
Heyne, H. O., Baez-Nieto, D. & Iqbal, S. et al. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. Sci. Transl. Med. 12, eaay6848 (2020).
Liu, C., Peres Kury, F. S., Li, Z., Ta, C., Wang, K. & Weng, C. Doc2Hpo: a web application for efficient and accurate HPO concept curation. Nucleic Acids Res. 47, W566–W570 (2019).
doi: 10.1093/nar/gkz386

Auteurs

Katherine Crawford (K)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Genetic Counseling, Arcadia University, Glenside, PA, USA.

Julie Xian (J)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Neuroscience Program, University of Pennsylvania, Philadelphia, PA, USA.

Katherine L Helbig (KL)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Peter D Galer (PD)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Shridhar Parthasarathy (S)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biology, The College of New Jersey, Ewing Township, NJ, USA.

David Lewis-Smith (D)

Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

Michael C Kaufman (MC)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Eryn Fitch (E)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Shiva Ganesan (S)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Margaret O'Brien (M)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Veronica Codoni (V)

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Colin A Ellis (CA)

The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

Laura J Conway (LJ)

Genetic Counseling, Arcadia University, Glenside, PA, USA.

Deanne Taylor (D)

Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Roland Krause (R)

Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.

Ingo Helbig (I)

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. helbigi@email.chop.edu.
The Epilepsy NeuroGenetics Initiative (ENGIN), Children's Hospital of Philadelphia, Philadelphia, PA, USA. helbigi@email.chop.edu.
Department of Biomedical and Health Informatics (DBHi), Children's Hospital of Philadelphia, Philadelphia, PA, USA. helbigi@email.chop.edu.
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. helbigi@email.chop.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH